Company Filing History:
Years Active: 2023-2024
Title: Innovations by Darren Locke in Cancer Treatment
Introduction
Darren Locke is an accomplished inventor based in Bordentown, NJ (US). He has made significant contributions to the field of cancer treatment, particularly in the development of methods for treating LAG-3 positive tumors. With a total of 2 patents, his work is paving the way for advancements in immunotherapy.
Latest Patents
Darren Locke's latest patents focus on the treatment of LAG-3 positive tumors. The invention provides a method of treating a tumor in a human patient by identifying the patient as having a LAG-3 positive tumor. The treatment involves administering a PD-1 pathway inhibitor, a combination of a PD-1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further includes identifying the patient as having a LAG-3 positive PD-L1 positive tumor. The LAG-3 inhibitor may be an anti-LAG-3 antibody, while the PD-1 pathway inhibitor may be an anti-PD-1 antibody. These methods aim to improve response rates to treatment with various inhibitors.
Career Highlights
Darren Locke is currently employed at Bristol-Myers Squibb Company, where he continues to innovate in the field of cancer research. His work is instrumental in developing therapies that enhance patient outcomes.
Collaborations
Darren collaborates with notable colleagues such as James Novotny, Jr. and Nils Lonberg. Their combined expertise contributes to the advancement of cancer treatment methodologies.
Conclusion
Darren Locke's contributions to the treatment of LAG-3 positive tumors represent a significant step forward in cancer therapy. His innovative approaches and collaborations are likely to have a lasting impact on the field.